Telomerase and its potential for therapeutic intervention

British Journal of Pharmacology

Volumn 152, Issue 7, 2007, Pages 1003-1011

  Phatak, P ^a   Burger, A M ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Bressler Research Building ^*  (United States)

Author keywords

G quadruplex; hTERC; hTERT; Telomerase; Telomere targeting agents; Telomere uncapping; Telomeres

Indexed keywords

17 AAG; 17 ALLYLAMINOGELDANAMYCIN; 17 DMAG; 3 AMINOBENZAMIDE; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ABT 888; ACRIDINE DERIVATIVE; AG 14361; ANTISENSE OLIGONUCLEOTIDE; BIBR 1532; BRACO 19; CISPLATIN; ETHIDUM DEIVATIVE; GRN 163; GRN 163L; HEAT SHOCK PROTEIN 90 INHIBITOR; HTERT VACCINE; PACLITAXEL; PORPHYRIN; PROTEIN SUBUNIT; RHPS 4; RNA; TELOMERASE; TELOMERASE INHIBITOR; TELOMESTATIN; UNCLASSIFIED DRUG; ZIDOVUDINE;

BREAST CANCER; CANCER RECURRENCE; CANCER STEM CELL; CANCER THERAPY; CATALYSIS; CELL PROLIFERATION; CELL TYPE; CLINICAL TRIAL; COMPLEX FORMATION; DNA DAMAGE; DNA REPLICATION; DNA STRUCTURE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; LUNG CANCER; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; STEM CELL MOBILIZATION; TELOMERE;

ANIMALS; CANCER VACCINES; ENZYME INHIBITORS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; NEOPLASMS; TELOMERASE; TELOMERE;

EID: 36448955418     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707374     Document Type: Review

References (92)

1. Armanios M, Greider CW (2005). Telomerase and cancer stem cells. Cold Spring Harb Symp Quant Biol 70: 205-208.
2. Bisoffi M, Heaphy CM, Griffith JK (2006). Telomeres: prognostic markers for solid tumours. Int J Cancer 119: 2255-2260.
3. Blackburn EH (1991). Structure and function of telomeres. Nature 305: 569-573.
4. Blackburn EH (1992). Telomerases. Annu Rev Biochem 61: 113-129.
5. Blackburn EH (2000). Telomere states and cell fates. Nature 408: 53-56.
6. Blackburn EH (2001). Switching, signaling at the telomere. Cell 106: 661-673.
7. Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA et al. (1997). Telomere shortening and tumour formation by mouse cells lacking telomerase RNA. Cell 91: 25-34.
8. Blasco MA (2003). Telomeres in cancer and aging: lessons from the mouse. Cancer Lett 194: 183-188.
9. Brown T, Sigurdson E, Rogatko A, Broccoli D (2003). Telomerase inhibition using azidothymidine in the HT-29 colon cancer cell line. Ann Surg Oncol 10: 910-915.
10. Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I et al. (2006). Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 55: 1553-1564.
11. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR (1995). Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 14: 4240-4248.
12. Burger AM, Bibby MC, Double JA (1997a). Telomerase activity in normal and malignant mammalian tissues: feasibility of telomerase as target for cancer chemotherapy. Br J Cancer 75: 516-522.
13. Burger AM, Dai F, Schultes CM, Reszka AP, Moore MJ, Double JA et al. (2005). The G-quadruplex interactive molecule BRACO19 inhibits tumour growth, consistent with telomere binding and interference with telomerase function. Cancer Res 65: 1489-1496.
14. Burger AM, Double JA, Newell DR (1997b). Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur J Cancer 33: 638-644.
15. Burger AM, Kelland LR (2006). Telomere targeting agents. In: Dawson N, Kelly (eds). Prostate Cancer: Translational and Emerging Therapies Chapter 12 Taylor & Francis Group, LLC: NY, pp 195-208.
16. Burger AM (1999). Telomerase in cancer diagnosis and therapy. BioDrugs 12: 413-422.
17. Burger AM (2007). Highlights in experimental therapeutics. Cancer Lett 245: 11-21.
18. Carpenter EL, Vonderheide RH (2006). Telomerase-based immunotherapy of cancer. Expert Opin Biol Ther 6: 1031-1039.
19. Cookson JC, Dai F, Smith V, Heald RA, Laughton CA, Stevens MFG et al. (2005a). Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl] acridinium methosulfate (RHPS4) in vitro: activity in human tumour cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents. Mol Pharmacol 68: 1551-1558.
20. Cookson JC, Heald RA, Stevens MF (2005b). Antitumour polycyclic acridines, 17, synthesis, and pharmaceutical profiles of pentacyclic acridinium salts designed to destabilize telomeric integrity. J Med Chem 48: 7198-7207.
21. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T et al. (2003). DNA damage checkpoint response in telomere-initiated senescence. Nature 426: 194-198.
22. Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, Priepke H et al. (2001). A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 20: 6958-6968.
23. Danet-Desnoyers GA, Luongo JL, Bonnet DA, Domchek SM, Vonderheide RH (2005). Telomerase vaccination has no detectable effect on SCID-repopulating and colony forming activities in the bone marrow of cancer patients. Exp Hematol 33: 1275-1280.
24. De Lange T (2002). Protection of mammalian telomeres. Oncogene 21: 532-540.
25. Dikmen ZG, Gellert GC, Jackson S, Gryaznov S, Tressler R, Dogan P et al. (2005). In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res 65: 7866-7873.
26. Donawho CK, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD et al. (2007). ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13: 2728-2737.
27. Fang G, Czech TR (1993). Characterization of a G-quartet formation reaction promoted by the beta-subunit of the Oxytricha telomere-binding protein. Biochemistry 32: 11646-11657.
28. Fearon EA, Vogelstein BA (1990). A genetic model for colorectal carcinogenesis. Cell 61: 759-767.
29. Feng J, Funk WD, Wang SS, Weinrich AA, Avilon CP, Chiu CP et al. (1995). The RNA component of human telomerase. Science 269: 1236-1241.
30. Fordyce CA, Heaphy CM, Bisoffi M, Wyaco JL, Joste NE, Mangalik A et al. (2006). Telomere content correlates with stage and prognosis in breast cancer. Breast Cancer Res Treat 99: 193-202.
31. Fordyce CA, Heaphy CM, Joste NE, Smith AY, Hunt WC, Griffith JK (2005). Association between cancer-free survival and telomere DNA content in prostate tumours. J Urol 173: 610-614.
32. Forsythe HL, Jarvis JL, Turner JW, Elmore LW, Holt SE (2001). Stable association of hsp90 and p23, but not hsp70, with active human telomerase. J Biol Chem 276: 15571-15574.
33. Gellert GC, Dikmen ZG, Wright WE, Gryaznov S, Shay JW (2006). Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res Treat 96: 73-81.
34. Goldstein S (1990). Replicative senescence: the human fibroblast comes of age. Science 249: 1129-1133.
35. Gomez D, Wenner T, Brassart B, Douarre C, O'Donohue MF, El Khoury V et al. (2006). Telomestatin-induced telomere uncapping is modulated by POT1 through G-overhang extension in HT1080 human tumour cells. J Biol Chem 281: 38721-38729.
36. Gonzalez-Suarez E, Samper E, Flores JM, Blasco MA (2000). Telomerase deficient mice with short telomeres are resistant to skin tumourigenesis. Nat Genet 26: 114-117.
37. Gowan S, Heald R, Stevens MFG, Kelland LR (2001). Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes. Mol Pharmacol 60: 981-988.
38. Greider CW (1991). Chromosome first aid. Cell 67: 645-647.
39. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA (1999a). Creation of human tumour cells with defined genetic elements. Nature 400: 464-468.
40. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A et al. (1999b). Inhibition of telomerase limits the growth of human cancer cells. Nat Med 5: 1164-1170.
41. Hamburger AW, Salmon SE (1977). Primary bioassay of human tumour stem cells. Science 197: 461-463.
42. Hanahan D, Weinberg RA (2000). The hallmarks of cancer. Cell 100: 50-70.
43. Hao LY, Armanios M, Strong MA, Karim B, Feldser DM, Huso D et al. (2005). Short telomeres, even in the presence of telomerase, limit tissue renewal capacity. Cell 123: 1121-1131.
44. Harley CB, Fuchter BA, Greider CW (1990). Telomeres shorten during ageing of human fibroblasts. Nature 345: 458-460.
45. Hastie ND, Dempster M, Dunlop MC, Thompson AM, Green DK, Allshire RC (1990). Telomere reduction in human colorectal carcinoma and with ageing. Nature 346: 866-868.
46. Hayflick L (1992). Aging, longevity, and immortality in vitro. Exper Gerontol 27: 363-368.
47. Herbert B, Pitts AE, Baker SI, Hamilton WE,Wright WE, Shay JW et al. (1999). Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci USA 96: 14276-14281.
48. Holt SE, Aisner DL, Baur J, Tesmer VM, Dy M, Ouellette M et al. (1999). Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev 13: 817-826.
49. Holt SE, Shay JW, Wright WE (1996). Refining the telomere-telomerase hypothesis of aging and cancer. Nat Biotechnol 14: 1734-1741.
50. Ishibashi T, Lippard SJ (1998). Telomere loss in cells treated with cisplatin. Proc Natl Acad Sci USA 95: 4219-4223.
51. Jackson SR, Zhu CH, Paulson V,Watkins L, Dikmen ZG, Gryaznov SM et al. (2007). Antiadhesive effects of GRN163L - an oligonucleotide N3′->P5′ thio-phosphoramidate targeting telomerase. Cancer Res 67: 1121-1129.
52. Ju Z, Rudolph KL (2006). Telomeres and telomerase in cancer stem cells. Eur J Cancer 42: 1197-1203.
53. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T (1999). P53 and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 283: 1321-1325.
54. Keith NW, Evans JTR, Glasspool RM (2001). Telomerase and Cancer: time to move from a promising target to a clinical trial. J Pathol 195: 404-414.
55. Keith WN, Bilsland A, Evans TR, Glasspool RM (2002). Telomerase-directed molecular therapeutics. Expert Rev Mol Med 22: 1-25.
56. Kelland LR (2001). Telomerase: biology and phase I trials. Lancet Oncol 2: 95-102.
57. Kelland LR (2005). Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics-current status and future prospectus. Eur J Cancer 41: 971-979.
58. Kim MY, Vankayalapati H, Shin-Ya K, Wierzba K, Hurley LH (2002). Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular G-quadruplex. J Am Chem Soc 124: 2098-2099.
59. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL et al. (1994). Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015.
60. Koga S, Kondo Y, Komata T, Kondo S (2001). Treatment of bladder cancer cells in vitro and in vivo with 2-5 A anti telomerase RNA. Gene Therapy 8: 654-658.
61. Kondo S, Kondo Y, Li G, Silverman RH, Cowel JK (1998). Targeted therapy of humanmalignant glioma in amousemodel by 2-5A antisense directed against telomerase RNA. Oncogene 16: 3323-3330.
62. Kushner DM, Paranjape JM, Bandyopadhyay B, Cramer H, Leaman DW, Kennedy AW et al. (2000). 2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells. Gynecol Oncol 76: 183-192.
63. Lundblad V, Blackburn EH (1993). An alternative pathway for yeast telomere maintenance rescues est-1 senescence. Cell 73: 347-360.
64. Mochizuki Y, He J, Kulkarni S, Bessler M, Mason PJ (2004). Mouse dyskerin mutations affect accumulation of telomerase RNA and small nucleolar RNA, telomerase activity, and ribosomal RNA processing. Proc Natl Acad Sci USA 101: 10756-10761.
65. Morin GB (1995). Is telomerase a universal cancer target? J Natl Cancer Inst 87: 859-861.
66. Murti KG, Prescott DM (1999). Telomeres of polytene chromosomes in a ciliated protozoan terminate in duplex DNA loops. Proc Natl Acad Sci USA 96: 14436-14439.
67. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J et al. (1997). Telomerase catalytic subunit homologs from fission yeast and human. Science 277: 955-959.
68. No authors listed. NIH Clinical Research Studies Protocol Number, 06-C-0172 http://clinicalstudies, info.nih.gov/detail/A_, 2006-C-0172, html.
69. Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA (2004). Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumours endogenously expressing telomerase. Clin Cancer Res 10: 4688-4698.
70. Parkinson GN, Lee MP, Neidle S (2002). Crystal structure of parallel quadruplexes from human telomeric DNA. Nature 417: 876-880.
71. Pennarun G, Granotier C, Gauthier LR, Gomez D, Hoffschir F, Mandine E et al. (2005). Apoptosis related to telomere instability and cell cycle alterations in human glioma cells treated by new highly selective G-quadruplex ligands. Oncogene 24: 2917-2928.
72. Phatak P, Cookson JC, Dai F, Smith V, Gartenhaus RB, Stevens MF et al. (2007). Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism. Br J Cancer 96: 1223-1233.
73. Plumb JA, Bilsland A, Kakani R, Zhao J, Glasspool RM, Knox RJ et al. (2001). Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene 20: 7797-7803.
74. Read M, Harrison RJ, Romagnoli B, Tanious FA, Gowan SH, Reszka AP et al. (2001). Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors. Proc Natl Acad Sci USA 98: 4844-4849.
75. Riou J-F, Guittat L, Mailliet P, Laoui A, Renou E, Petitgenet O et al. (2002). Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands. Proc Natl Acad Sci USA 99: 2672-2677.
76. Salvati E, Leonetti C, Rizzo A, Scarsella M, Mottolese M, Galati R et al. (2007). Telomere damage promotes antitumoural activity of the G-quadruplex ligand RHPS4. J Clinc Invest (in press).
77. Saretzki G, Ludwig A, Zglinicki T, Runnebaum IB (2001). Ribozyme-mediated telomerase inhibition induced immidiate cell loss but not telomere shortening i ovarian cancer cells. Cancer Gene Ther 8: 827-834.
78. Sarin KY, Cheung P, Gilison D, Lee E, Tennen RI, Wang E et al. (2005). Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature 436: 1048-1052.
79. Seimiya H, Muramatsu Y, Tomokazu O, Tsuruo T (2005). Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell 7: 25-37.
80. Shay JW, Bacchetti S (1997). A survey of telomerase activity in human cancer. Eur J Cancer 33: 787-791.
81. Shay JW (2003). Telomerase therapeutics: telomeres recognized as a DNA damage signal. Clin Cancer Res 9: 3521-3525.
82. Shippen DE (1993). Telomeres and telomerases. Curr Opinion Genet Devel 3: 759-763.
83. Smith CD, Blackburn EH (1999). Uncapping and deregulation of telomeres lead to detrimental cellular consequences in yeast. J Cell Biol 145: 203-214.
84. Smith S, Giriat I, Schmitt A, de Lange T (1998). Tankyrase, a poly(ADP-ribose)polymerase at human telomeres. Science 282: 1484-1487.
85. Strahl C, Blackburn EH (1996). Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 16: 53-65.
86. Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S et al. (2007). Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 3: 945-956.
87. Van Steensel B, de Lange T (1997). Control of telomere length by the human telomeric binding protein TRF1. Nature 385: 740-743.
88. Villa R, Folini M, Porta CD, Valentini A, Pennati M, Daidone MG et al. (2003). Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells. Carcinogenesis 24: 851-859.
89. Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY et al. (2004). Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 10: 828-839.
90. Wang Y, Patel DJ (1993). Solution structure of the human telomeric repeat d[AG3(T2AG3)3] G-tetraplex. Structure 1: 263-282.
91. Wright WE, Shay JW (2005). Mechanism-based combination telomerase inhibition therapy. Cancer Cell 7: 1-2.
92. Yatabe N, Kyo S, Kondo S, Kanaya T, Wang Z, Maida Y et al. (2002). 2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells. Cancer Gene Ther 9: 624-630.